Test Price
1,800 AED✅ Home Collection Available
von Willebrand Factor Antigen (vWF:Ag) Test in UAE | 1,800 AED | DHA-Compliant Coagulation Panel
Executive Summary & Core Metrics
The von Willebrand Factor Antigen (vWF:Ag) Test precisely quantifies the circulating plasma concentration of von Willebrand factor, a multimeric glycoprotein critical for platelet adhesion at sites of vascular injury and for stabilizing coagulation factor VIII against proteolytic degradation. Measurement of vWF:Ag is the foundational screening assay for von Willebrand Disease (VWD), the most prevalent inherited bleeding disorder worldwide, with an estimated symptomatic prevalence of 1 in 1,000 individuals. Our laboratory employs Chemiluminescent Immunoassay (CLIA) technology on platelet-poor plasma, achieving an ultra-trace analytical sensitivity of 0.5 IU/dL and a broad dynamic range spanning 0.5–500 IU/dL, ensuring accurate detection across all VWD subtypes including mild type 1 deficiencies. All testing is performed under ISO 9001:2015 accredited workflows (Cert: INT/EGQ/2509DA/3139) within our DHA-licensed facility at Dubai Healthcare City. Results are delivered same-day by 6 PM for samples received by Wednesday 11 AM. Our VIP Mobile Phlebotomy service provides hospital-grade home collection with ISO-certified temperature-controlled cold-chain logistics across all Emirates, available daily from 8 AM to 11 PM. Direct insurance billing verification and post-test telephonic clinical guidance are accessible via WhatsApp at +971 54 548 8731.
VIP Home Collection
8 AM – 11 PM • Cold-Chain Logistics
Post-Test Guidance
Telephonic Clinical Consultation
WhatsApp Insurance Check
+971 54 548 8731
99.9% Diagnostic Sensitivity
ISO 9001:2015 Certified
Test Overview & Methodology
Von Willebrand factor is a large, multimeric adhesive glycoprotein synthesized in endothelial cells and megakaryocytes, stored in Weibel-Palade bodies and platelet alpha-granules, and released into plasma where it circulates as a series of multimers ranging from 500 to over 20,000 kDa. The protein performs two essential hemostatic functions: it mediates the initial adhesion of platelets to exposed subendothelial collagen at sites of vascular injury via binding to platelet glycoprotein Ib (GPIb), and it serves as the specific carrier protein for coagulation factor VIII, protecting it from rapid clearance by the low-density lipoprotein receptor-related protein (LRP). Quantitative deficiency of vWF — whether partial (type 1 VWD), qualitative dysfunction (type 2 VWD), or near-complete absence (type 3 VWD) — results in impaired platelet plug formation and reduced factor VIII activity, manifesting clinically as mucocutaneous bleeding, prolonged bleeding after surgery or dental extraction, menorrhagia, and in severe cases, hemarthroses and soft-tissue hematomas. In populations with elevated consanguinity rates, the prevalence of autosomal recessive type 3 VWD is disproportionately higher, making accurate quantitative vWF:Ag testing a cornerstone of the diagnostic hemostasis evaluation.
| Parameter | DNA Labs UAE (CLIA) | Alternative (ELISA) |
|---|---|---|
| Methodology | Chemiluminescent Immunoassay (CLIA) | Enzyme-Linked Immunosorbent Assay (ELISA) |
| Analytical Sensitivity | 0.5 IU/dL (Ultra-Trace Detection) | ~1.5 IU/dL |
| Turnaround Time | Same Day by 6 PM | 2–3 Working Days |
| Sample Stability | PPP Frozen • Strict Cold-Chain | Variable • Batch Processing |
| Accreditation | ISO 9001:2015 • DHA-Compliant | Varies by Facility |
| Price | 1,800 AED | 1,200–2,000 AED (Range) |
Physician Insight & Safety Protocols
Dr. Ajay Singh
General Practitioner • DHA Registration ID: 36234132
"The vWF:Ag assay is the quantitative gatekeeper of the hemostasis workup, but it must never be interpreted as a standalone result. I always request a simultaneous factor VIII activity and a functional vWF assay such as ristocetin cofactor activity or the newer GPIbR binding assay, because a normal vWF:Ag level does not exclude type 2 VWD variants where the protein is present but dysfunctional. Furthermore, blood group O individuals have naturally lower vWF levels — typically 25–30% below those of non-O subjects — so a result of 40 IU/dL in a group O patient may be physiologically normal, whereas the same value in a group AB patient signals a genuine deficiency. Clinical context is everything: stress, acute illness, surgery, pregnancy, and estrogen therapy all elevate vWF as an acute-phase reactant, potentially masking a deficiency state. I advise repeat testing during a period of sustained clinical stability before committing to a diagnosis of VWD."
Critical Medication Advisory
⚠️ Pre-Test Anticoagulant Management
Do not discontinue prescribed medication without consulting your treating physician. Heparin must be withheld for 24 hours and oral anticoagulants (e.g., warfarin, rivaroxaban, apixaban, dabigatran) for 7 days prior to blood sampling — but only with the explicit prior consent and guidance of your doctor. Abrupt cessation of anticoagulant therapy without medical supervision can precipitate life-threatening thromboembolic events including stroke, pulmonary embolism, and deep vein thrombosis. All medication adjustments must be physician-directed and documented in the patient record.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Collect)
- Active uncontrolled bleeding or hemodynamic instability — proceed directly to emergency care
- Acute febrile illness or systemic infection (vWF is an acute-phase reactant; values will be unreliable)
- Recent major surgery or significant trauma within 14 days
- Current pregnancy or immediate postpartum period (physiologic vWF elevation confounds interpretation)
- Strenuous exercise within 24 hours (transiently elevates vWF levels)
- Severe lipemia, hemolysis, or icterus precluding viable platelet-poor plasma preparation
Emergency Red Flags — Seek Immediate Care
- Spontaneous joint hemorrhage (hemarthrosis) with swelling, warmth, and loss of range of motion
- Unprovoked intramuscular hematoma causing compartment syndrome symptoms
- Persistent epistaxis unresponsive to 20 minutes of sustained direct pressure
- Gastrointestinal bleeding evidenced by hematemesis, melena, or hematochezia
- Heavy menstrual bleeding with hemodynamic compromise (tachycardia, orthostatic hypotension, syncope)
- Prolonged uncontrolled bleeding following any dental extraction or minor surgical procedure
Patient FAQ & Clinical Guidance
1. What is the von Willebrand Factor Antigen test and why is it ordered?
The vWF:Ag test measures the total protein concentration of von Willebrand factor circulating in your plasma, serving as the essential first-line screening assay when a patient presents with unexplained easy bruising, prolonged bleeding from minor wounds, recurrent epistaxis, heavy menstrual bleeding, or a family history suggestive of a bleeding disorder. Physicians order this test as part of a comprehensive hemostasis panel — alongside factor VIII activity and a functional vWF assay — to diagnose or exclude von Willebrand Disease, particularly before elective surgery, dental extractions, or when evaluating any personal or family history of coagulopathy. Early and accurate diagnosis enables targeted prophylactic therapy and prevents hemorrhagic complications during invasive procedures.
2. Do I need to fast before the vWF:Ag blood test and which medications affect results?
Overnight fasting for 8 to 12 hours is strongly recommended because lipemic (fatty) plasma can interfere with the chemiluminescent detection system, and multiple medications — including heparin, warfarin, direct oral anticoagulants, aspirin, and NSAIDs — can significantly alter measured vWF antigen levels. Heparin must be paused for 24 hours and oral anticoagulants for 7 days before the blood draw, but only with explicit written consent from your treating physician. Never stop prescribed blood thinners independently. Estrogen-containing contraceptives, hormone replacement therapy, and pregnancy physiologically elevate vWF levels; inform your physician of all medications, supplements, and hormonal status at the time of testing.
3. What do abnormal or low vWF Antigen results mean for my health?
A low vWF:Ag level — typically below 30–50 IU/dL depending on blood group and laboratory reference range — indicates a quantitative deficiency of von Willebrand factor consistent with type 1 (partial deficiency) or type 3 (near-complete absence) von Willebrand Disease, requiring further subtyping with functional assays and multimer analysis. Blood group O individuals naturally have vWF levels approximately 25–30% lower than non-O individuals, so a borderline low result in a group O patient may be constitutional rather than pathological. Mildly reduced levels cause subtle bleeding tendencies, while severely depressed levels (below 10 IU/dL) confer risk of spontaneous joint and soft-tissue hemorrhage. Your hematologist will integrate your vWF:Ag result with vWF functional activity, factor VIII activity, and multimer distribution to classify the VWD subtype and formulate a personalized treatment plan.
4. How is the sample collected and what is the turnaround time?
A 3 mL whole blood sample is collected in a single light-blue top tube containing 3.2% sodium citrate anticoagulant, mixed gently by inversion, and processed to platelet-poor plasma within 1 hour of collection. Our VIP Mobile Phlebotomy service provides hospital-grade home collection with ISO-certified cold-chain transport, available daily from 8 AM to 11 PM across all Emirates. For samples received at our laboratory by Wednesday 11 AM, results are reported same-day by 6 PM. Direct insurance billing verification is available via WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
Legal & Data Privacy Framework
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — Patient Data Privacy
- Federal Law No. 2 of 2019 — Use of ICT in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability — Clinical Safety & Patient Consent
- DHA Facility License: 1143
Quality & Accreditation Standards
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139)
- DHA/MOHAP Standard Nomenclature Compliance
- CLIA Methodology Validated per CLSI H47-A2 Guidelines
- External Quality Assurance: UK NEQAS Blood Coagulation
Clinical Coding & Classification
- ICD-10-CM: D68.0 (von Willebrand Disease)
- ICD-10-CM: D68.9 (Coagulation Defect, Unspecified)
- ICD-10-CM: Z14.8 (Genetic Carrier — VWD Susceptibility)
- LOINC: 6014-7 — vWF Ag [Mass/Vol] in Platelet-Poor Plasma
Clinical & Logistical Metadata
| Test Name | von Willebrand Factor Antigen (vWF:Ag) Test |
| Price (AED) | 1,800 AED |
| Turnaround Time | Same Day by 6 PM (Sample cutoff: Wednesday 11 AM) |
| Sample Type / Matrix | Peripheral Whole Blood (3 mL in 3.2% Sodium Citrate Blue Top Tube) → Platelet-Poor Plasma (PPP) |
| Methodology Used | Chemiluminescent Immunoassay (CLIA) |
| ICD-10-CM Code | D68.0, D68.9, Z14.8 |
| LOINC Code | 6014-7 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
📞 Book Your vWF:Ag Test Today
WhatsApp Insurance Verification • VIP Home Collection 8 AM–11 PM • Same-Day Results by 6 PM
+971 54 548 8731
DHA Facility License: 1143 • ISO 9001:2015 • All Emirates Service Coverage • DNA Labs UAE
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians